Status:

COMPLETED

Phosphate Lowering in CKD Trial

Lead Sponsor:

VA Office of Research and Development

Conditions:

Chronic Kidney Disease

Cardiovascular Disease

Eligibility:

All Genders

40-79 years

Phase:

PHASE4

Brief Summary

The proposed research is a randomized-controlled trial to determine the effectiveness of reducing serum phosphorus using a phosphate binder, lanthanum carbonate, for improving the function of arteries...

Detailed Description

Chronic kidney disease (CKD) is a major health concern both in the general and Veteran populations. Indeed, the prevalence of CKD in a large Veteran population is 20%. Cardiovascular disease (CVD) is ...

Eligibility Criteria

Inclusion

  • Age 40-79, women must be post-menopausal
  • CKD stage IIIb or IV (estimated glomerular filtration rate by MDRD 15-45 mL/min/1.73m2), stable for 3 months
  • Serum phosphorus 2.8-5.5 mg/dL, stable for 3 months
  • Not using phosphate binders
  • Albumin \> 3.0 g/dL
  • Free from alcohol dependence or abuse
  • Ability to provide informed consent
  • BMI \< 40 kg/m2
  • Not taking medications that interact with agents administered during experimental sessions (e.g., sildenafil interacts with nitroglycerin)
  • For COMIRB 15-0384, completion of the prospective, randomized, placebo-controlled double-blind trial, Phosphorus Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease (COMIRB 13-0328) or completion of 12-week run-in phase

Exclusion

  • Life expectancy \<1 year
  • Uncontrolled hypertension
  • History of severe liver disease
  • History of congestive heart failure (EF \< 35%)
  • History of hospitalizations within the last 3 months
  • History of ileus or bowel obstruction
  • Active infection or antibiotic therapy
  • Expected kidney transplant in the next 6 months
  • Active vitamin D analogue use (i.e. calcitriol, paricalcitol, doxercalciferol)
  • Vasculitis requiring immunosuppressive therapy within the last year
  • Current tobacco abuse

Key Trial Info

Start Date :

September 15 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 20 2019

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT02209636

Start Date

September 15 2014

End Date

December 20 2019

Last Update

August 26 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rocky Mountain Regional VA Medical Center, Aurora, CO

Aurora, Colorado, United States, 80045